Literature DB >> 29636998

EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.

Yi-Chung Chien1,2, Liang-Chih Liu3,4, Han-Yu Ye1,2, Jia-Yan Wu1,2, Yung-Luen Yu1,2,5.   

Abstract

Triple-negative breast cancer (TNBC) has a higher potential for invasion and metastasis than other types of breast cancer. Enhancer of zeste homolog 2 (EZH2) is the catalytic core protein in the polycomb repressive complex 2 (PRC2), which catalyzes the trimethylation of histone H3 at lysine 27 (H3K27me3) and mediates gene silencing of the target genes that are involved in fundamental cellular processes, such as the cell fate decision, cell cycle regulation, senescence, cell differentiation, and cancer formation. A consistent association between TNBC metastasis and EZH2 has not been confirmed. The aim of this study was to investigate the role of EZH2 in the regulation of tissue inhibitor of metalloproteinase (TIMPs) and matrix metalloproteinases (MMPs) to promote metastasis of TNBC cells and to characterize the metastasis-associated genes regulated by EZH2 in TNBC cells. We found that high levels of EZH2 expression induce repression of TIMP2 transcription, leading to increased activity of MMP-2 and MMP-9 and thus to increased invasive activity of TNBC cells.

Entities:  

Keywords:  Enhancer of zeste homolog 2; matrix metalloproteinases; migration; tissue inhibitor of metalloproteinase; triple-negative breast cancer cell

Year:  2018        PMID: 29636998      PMCID: PMC5883093     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  31 in total

Review 1.  Polycomb repression: from cellular memory to cellular proliferation and cancer.

Authors:  Jacqueline J L Jacobs; Maarten van Lohuizen
Journal:  Biochim Biophys Acta       Date:  2002-06-21

2.  The Drosophila pho-like gene encodes a YY1-related DNA binding protein that is redundant with pleiohomeotic in homeotic gene silencing.

Authors:  J Lesley Brown; Cornelia Fritsch; Jürg Mueller; Judith A Kassis
Journal:  Development       Date:  2003-01       Impact factor: 6.868

3.  YY1 DNA binding and PcG recruitment requires CtBP.

Authors:  Lakshmi Srinivasan; Michael L Atchison
Journal:  Genes Dev       Date:  2004-11-01       Impact factor: 11.361

Review 4.  Polycombing the genome: PcG, trxG, and chromatin silencing.

Authors:  V Pirrotta
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

Review 5.  PcG complexes and chromatin silencing.

Authors:  V Pirrotta
Journal:  Curr Opin Genet Dev       Date:  1997-04       Impact factor: 5.578

Review 6.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

Review 7.  General mechanisms of metastasis.

Authors:  E C Woodhouse; R F Chuaqui; L A Liotta
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

8.  Regulation of transcription factor YY1 by acetylation and deacetylation.

Authors:  Y L Yao; W M Yang; E Seto
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

9.  Isolation and characterization of MUC15, a novel cell membrane-associated mucin.

Authors:  Lone T Pallesen; Lars Berglund; Lone K Rasmussen; Torben E Petersen; Jan T Rasmussen
Journal:  Eur J Biochem       Date:  2002-06

Review 10.  The role of EZH2 in tumour progression.

Authors:  C-J Chang; M-C Hung
Journal:  Br J Cancer       Date:  2011-12-20       Impact factor: 7.640

View more
  24 in total

1.  Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer.

Authors:  Nana Zheng; Lixia Wang; Yingying Hou; Xiuxia Zhou; Youhua He; Zhiwei Wang
Journal:  Cell Cycle       Date:  2018-11-15       Impact factor: 4.534

2.  Natriuretic peptide receptor a promotes breast cancer development by upregulating MMP9.

Authors:  Jingkun Qu; Xixi Zhao; Xu Liu; Yuchen Sun; Jizhao Wang; Lin Liu; Jiansheng Wang; Jia Zhang
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

3.  Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer.

Authors:  Zegui Tu; Xiancheng Chen; Tian Tian; Guo Chen; Meijuan Huang
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

4.  [Agkistrodon halys venom antitumor component-I inhibits vasculogenic mimicry in triple-negative breast cancer cells in vitro by down-regulating MMP2].

Authors:  Y Ge; L Lu; S Tian; Y Xiao; S Xie; Q Wang; H Zhi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-03-20

5.  [Association of JMJD3, MMP-2 and VEGF expressions with clinicopathological features of invasive ductal breast carcinoma].

Authors:  Xiaoyan Xu; Jianjun Wang; Chen Yan; Yingli Men; Huang Jiang; Huijuan Fang; Xianwei Xu; Jinhua Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

6.  Sevoflurane Offers Neuroprotection in a Cerebral Ischemia/Reperfusion Injury Rat Model Through the E2F1/EZH2/TIMP2 Regulatory Axis.

Authors:  Lihua Yang; Hongfei Chen; Lina Guan; Yucan Xu
Journal:  Mol Neurobiol       Date:  2022-01-22       Impact factor: 5.590

Review 7.  Epigenetic Regulation of Intestinal Stem Cells and Disease: A Balancing Act of DNA and Histone Methylation.

Authors:  Alireza Lorzadeh; Maile Romero-Wolf; Ajay Goel; Unmesh Jadhav
Journal:  Gastroenterology       Date:  2021-03-26       Impact factor: 33.883

8.  GSK343 induces autophagy and downregulates the AKT/mTOR signaling pathway in pancreatic cancer cells.

Authors:  Hao Xu; Linshi Zhang; Xiaohui Qian; Xiaohu Zhou; Yingcai Yan; Jiarong Zhou; Wenhao Ge; Mugahed Albahde; Weilin Wang
Journal:  Exp Ther Med       Date:  2019-08-02       Impact factor: 2.447

9.  NF-κB/NKILA signaling modulates the anti-cancerous effects of EZH2 inhibition.

Authors:  Suzann Duan; Westin K Chan; Andrew Oman; Dominic P Basile; Cristina M Alvira; Iain L O Buxton; Cristiana Iosef
Journal:  J Cell Mol Med       Date:  2019-07-07       Impact factor: 5.310

10.  AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.

Authors:  Jeffrey R White; Dakota T Thompson; Kelsey E Koch; Boris S Kiriazov; Anna C Beck; Dana M van der Heide; Benjamin G Grimm; Mikhail V Kulak; Ronald J Weigel
Journal:  Cancer Res       Date:  2021-07-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.